ʻO ka lawe ʻana i ka home no ʻEulopa, US, Kanada, Australia!
E ʻoluʻolu: ʻAʻole ʻae ʻo AASraw i nā mea kūʻai aku.

Vardenafil HCL pauka

Nā inoa'ē aʻe:Vardenafil pauka, Levitra pauka, Staxyn pauka, Vivanza pauka

ʻO AASraw ka ʻoihana mea hana o Vardenafil hydrochloride raw pauka nona ka hale hana kūʻokoʻa a me ka hale hana nui e like me ke kākoʻo, e hoʻokō ʻia nā hana āpau ma lalo o ka hoʻoponopono CGMP a me ka ʻōnaehana mālama maikaʻi trackable. KANAKA!

ʻŌlelo wikiwiki no ke kauoha liʻiliʻi

Inā pono ʻoe e kūʻai i kēia huahana ma ka nui, e ʻoluʻolu e hoʻohana i ke kahawai VIP e kiʻi i ke kumukūʻai hoʻokūkū loa.?

Kauoha Nui

Product Description

ʻO Vardenafil Hydrochloride Puka wikiō-AASraw

maka ʻO Vardenafil HCL Nā Kiʻi Kumu Paʻa

Name: ʻO Vardenafil hydrochloride (Levitra) ka lepo
CAS: 224785-91-5
Kaulike Molecular: C22H19N3O4
Kaumaha Molecular: 389.4
Wahi Manaʻo: 298-300 ° C
Hōʻoia Kōkua: 20ºC
kala like 'ole: Ka Lulu Maʻemaʻe

He aha ka Vardenafil hydrochloride Powder?

ʻO Vardenafil hydrochloride pauka, i kapa ʻia ʻo vardenafil HCL pauka, ʻo ia kekahi o ka enzyme phosphodiesterase type 5 (PDE5) mea hoʻopaneʻe. ʻO kēia enzyme ke kuleana no ka hoʻohaʻahaʻa ʻana i ka cyclic guanosine monophosphate (cGMP), a mole e hana koʻikoʻi i ka hana erectile.

I ka wā o ka moe kolohe, hoʻokuʻu ʻia ka nitric oxide i loko o ke kino erectile o ka penis (corpus cavernosum), a laila hoʻoulu i ka enzyme guanylate cyclase. Hoʻonui kēia enzyme i nā kiʻekiʻe o cGMP, kahi e hoʻomaha ai i nā ʻiʻo maʻemaʻe i loko o ka corpus cavernosum. ʻO ka hoʻomahaʻana o kēia mauʻiʻo e hiki ai i ke koko ke kahe i loko o ka penis, e alakaʻi ana i kahi kūkulu.

Ma ke kāohi ʻana iā PDE5, AASraw vardenafil hydrochloride pauka pale i ka haʻihaʻi ʻana o cGMP, pēlā e mālama ai i nā pae kiʻekiʻe o kēia mole a hoʻolōʻihi i kona hopena. ʻO kēia ka hopena i ka hoʻomaha hoʻomaha ʻana o ka ʻiʻo a me ke kahe o ke koko, a laila e kōkua ai i ka mālama ʻana i ke kūkulu ʻana i ka wā o ka moekolohe.

Pehea e hana ai ka Vardenafil hydrochloride Powder?

Hana ʻo Vardenafil hydrochloride pauka ma ke ʻano he mea hoʻopale koho o kahi enzyme i kapa ʻia ʻo phosphodiesterase type 5 (PDE5). Eia kahi pani-ma-ka anu u alakai pehea e hana ai:

①Hoʻoulu ka hoʻoulu ʻana i ka wahine i ka hoʻokuʻu ʻana o ka nitric oxide i loko o ka corpus cavernosum, kahi ʻāpana o ka penis.

②Hoʻomaka kēia nitric oxide i kahi enzyme i kapa ʻia ʻo guanylate cyclase e hoʻololi i ka guanosine triphosphate (GTP) i cyclic guanosine monophosphate (cGMP).

③Hoʻomaha ka cGMP i nā ʻiʻo maʻemaʻe o ka corpus cavernosum, kahi e hiki ai i nā kīʻaha koko ke hoʻonui.

④ ʻO ka hoʻomāhuahua ʻana o nā kīʻaha koko e hoʻonui i ke kahe o ke koko i loko o ka penis, e alakaʻi ana i kahi kūkulu.

⑤ ʻO ka maʻamau, hoʻopau ka enzyme PDE5 i ka cGMP, hoʻopau i ke kūkulu ʻana. Hana ʻo Vardenafil hydrochloride ma ke kāohi ʻana i ka hana o PDE5, no laila e ʻae ai i ka cGMP e noho lōʻihi a hoʻolōʻihi i ke kūkulu ʻana.

⑥ ʻO ka hope loa, hoʻonui a hoʻomau ka vardenafil hydrochloride i ke kaʻina hana ola e alakaʻi ai i kahi kūkulu ʻana i ka pane ʻana i ka hoʻoulu wahine.

He mea nui e hoʻomaopopo i ka vardenafil hydrochloride ʻaʻole i hoʻokumu pololei i kahi kūkulu. Akā, ʻo ia hoʻonui i ka pane kūlohelohe o ke kino i ka moekolohe hoʻoulu ʻana. Eia kekahi, he mea nui ia kūʻai i ka pauka vardenafil hydrochloride mai kahi mea hoʻolako pono e like me AASraw, nāna i hoʻolako i ka vardenafil hcl pauka no nā makahiki he nui.

ʻO Vardenafil VS.Avanafil VS.Tadalafil VS.Sildenafil

ʻO nā mea hoʻopiʻi PDE5 maʻamau ʻehā ma ka mākeke ʻo sildenafil, hoʻopālaha, vardenafil, a me avanafil. ʻO kēia mau lāʻau lapaʻau ʻehā, ʻo ia ka PDE5 inhibitors a ʻo ia ka lālani mua o ka mālama ʻana no ED. Eia nō naʻe, ʻokoʻa ke ʻano o nā molekala kemika o kēia mau lāʻau lapaʻau ʻehā, e hopena i nā hana kemika a me ke kino. ʻO ka hopena, ʻokoʻa kā lākou absorption, ka hāʻawi ʻana, ka metabolism, a me ka excretion i ke kino, e like me kā lākou hopena curative.

PDE5 Kāohi Hoomaka o ka hana Tmax (h) Cmax (ng/ml) T1/2 (h) Ka lōʻihi (h) ʻO nā hana ʻino nui
ʻO Sildenafil 30min-1h 0.8-1 560 2.6-3.7 4 ʻO ka ʻeha o ke poʻo, ka ʻulaʻula o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūhā, ka ʻike ʻole
Kalaupapa 15 min 0.9 200 3.9 8 ʻO ka ʻeha o ke poʻo, ka ʻulaʻula o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūhā, ka ʻike ʻole
ʻO Tadalafil 1h 2 378 17.5 36 ʻO ka ʻeha o ke poʻo, ka ʻili ʻana o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūlū, ʻaʻohe mea ʻike ʻole
Avanafil 10-15 min / > 1000 3-5 6-8 ʻO ka ʻeha o ke poʻo, ka ʻili ʻana o ka maka, ka ʻai ʻana, ka nasal congestion, dizziness (emi pinepine ke hoʻohālikelike ʻia me nā mea ʻē aʻe)

'Ōlelo Aʻo:

Tmax = ka manawa e hiki ai ke kiʻekiʻe o ka plasma concentration

ʻO Cmax = ka nui o ka plasma koko

T1/2 = hapalua ola

Hōʻuluʻulu kēia papa ʻaina i nā ʻano pharmacokinetic o nā ʻehā PDE5 inhibitors i kūkākūkā ʻia. He mea nui i nā mea mālama ola ke noʻonoʻo i kēia mau ʻokoʻa ke kau ʻana i kēia mau lāʻau lapaʻau, a pono nā mea maʻi e hoʻohana mau i kēia mau lāʻau ma lalo o ka nānā ʻana o ke kauka. Eia kekahi, kūʻai i ka pauka vardenafil hcl mai kahi mea hoʻolako hilinaʻi e like me KANAKA hōʻoiaʻiʻo e loaʻa iā ʻoe kahi huahana o ka maikaʻi a me ka maʻemaʻe. ʻO AASraw, ma keʻano he mea hoʻolakoʻoihana vardenafil hcl pauka, hiki ke hoʻolako i ka vardenafil hydrochloride pauka me ke kūlana kiʻekiʻe ma ka honua holoʻokoʻa.

Pehea e koho ai i ka PDE5 inhibitors?

ʻO ke koho ʻana i ka mea hoʻopaneʻe PDE5 kūpono hiki ke hilinaʻi i nā ʻano kumu like ʻole, me ke olakino holoʻokoʻa o ka mea maʻi, ke kū ʻana o nā kūlana ʻē aʻe, ko lākou nohona, a me kā lākou pane ʻana i ka lāʻau lapaʻau. Eia kahi alakaʻi maʻamau no ke koho ʻana i kahi mea hoʻopaneʻe PDE5 no ka ʻike, akā e hoʻomanaʻo e kūkākūkā mau me kahi mea mālama ola e hana i ka koho maikaʻi loa no nā pono pilikino.

Kūlana hoʻomanawanui Paipai ʻia ʻo PDE5 Inhibitor kumu
He makemake no ka manawa hoʻomaka wikiwiki Avanafil ʻO ka hoʻomaka wikiwiki loa ma waena o ka PDE5 inhibitors
ʻO nā makahiki waena a me nā ʻelemakule me ED a me nā maʻi maʻi (hypertension, hyperlipidemia) ʻO Sildenafil ʻO nā ʻāpana pharmacokinetic maʻamau, emi ka hoʻoulu ʻana i ke kino
ʻO ka makahiki waena a me ka ʻelemakule me ED a me ka vascular endothelial dysfunction (egdiabetes) ʻO Tadalafil ʻO ka lōʻihi o ka hana, hiki ke hoʻomaikaʻi i ka hana endothelial vascular a me nā hōʻailona urinary tract i ka manawa
ʻO nā makahiki waena a me nā ʻelemakule me ED, ʻaʻohe maʻi vascular Kalaupapa He hopena maʻalahi, hoʻomaka wikiwiki, bioavailability haʻahaʻa, liʻiliʻi nā hopena ʻino
ʻO ka makahiki waena a me ka ʻelemakule me ED, vascular endothelial dysfunction, sildenafil ineffective Avanafil ʻO ke koko kiʻekiʻe, kahi hopena ikaika
ʻO nā ʻōpio a me nā makahiki waena me ED, ʻaʻohe etiology kūlohelohe ʻO Sildenafil Pono no ED ma muli o nā kumu noʻonoʻo
ʻO ka hana ʻike ʻole a me ED ʻO Tadalafil ʻAʻohe mea ʻikeʻole i waena o nā hopena ʻino
ʻO ka makemake o ka lāʻau lapaʻau postprandial ʻO Avanafil, Vardenafil ʻAʻole maʻalahi ka hoʻopili ʻana e ka meaʻai

Nota: Hāʻawi ʻia kēia ʻike e pili ana i nā mea hoʻopaneʻe PDE5 no nā kumu ʻike maʻamau wale nō a ʻaʻole ia he ʻōlelo aʻoaʻo olakino. Pono e hana mau ʻia ke koho ʻana i kahi mea hoʻopaneʻe PDE5 ma ke kūkākūkā ʻana me kahi mea mālama olakino hiki ke noʻonoʻo i ke olakino holoʻokoʻa o kēlā me kēia kanaka, nā lāʻau ʻē aʻe e lawe ʻia ana, a me ke ʻano kikoʻī a me ka paʻakikī o ka erectile dysfunction. ʻOiai hiki i kēia mau lāʻau lapaʻau ke hana maikaʻi i ka mālama ʻana i ka erectile dysfunction, loaʻa pū kekahi aoao waiwai a me nā pilikia, a ʻaʻole kūpono ia no kēlā me kēia. Hiki i kekahi mau maʻi olakino a me nā lāʻau lapaʻau ʻē aʻe ke launa pū me nā mea paʻa PDE5, e alakaʻi ana i nā hopena koʻikoʻi koʻikoʻi. E ʻimi mau i ka ʻōlelo aʻoaʻo o kahi mea mālama ola no nā nīnau āu e pili ana i kahi maʻi olakino.

ʻO ka dosage a me ka hoʻokele ʻana o Vardenafil hydrochloride Powder no ka kuhikuhi

ka ka nui o ka pauka vardenafil HCL Hiki ke ʻokoʻa ma muli o ke olakino o kēlā me kēia kanaka, ka pane ʻana i ka mālama ʻana, a me nā lāʻau lapaʻau ʻē aʻe a lākou e lawe ai. Eia nā ʻōlelo aʻoaʻo maʻamau, akā pono e hahai i nā ʻōlelo kikoʻī a kāu mea mālama ola.

hae dose no erectile dysfunction

ʻO ka nui o ka vardenafil i manaʻo ʻia he 10 mg, lawe waha ʻia ma kahi o 60 mau minuke ma mua o ka hana moekolohe. Hiki ke hoʻonui ʻia ka nui i ka 20 mg a i ʻole e hoʻemi i ka 5 mg, e pili ana i ka pono a me ka hoʻomanawanui. ʻO ka nui loa o ka hoʻohana ʻana i hoʻokahi manawa i kēlā me kēia lā.

ʻO nā maʻi me mʻoluʻolu hepatic ihōʻemi

No nā poʻe maʻi me ka maʻi hepatic haʻahaʻa (Child-Pugh B), ua ʻōlelo ʻia kahi ʻano hoʻomaka o 5 mg o vardenafil. ʻAʻole pono e ʻoi aku ka nui o ka nui i nā mea maʻi me ka maʻi hepatic haʻahaʻa ma mua o 10 mg.

ʻO nā maʻi me smau loa renal ihōʻemi

No nā poʻe maʻi me ka maʻi hōʻeha koʻikoʻi (CLcr <30 mL / min), hoʻomaka ka 5 mg o vardenafil.

Nā maʻi ma spapaʻaina alpha-bpale laka tlāʻau lapaʻau

ʻO ka hoʻomaka ʻana o ka vardenafil no ka poʻe maʻi e loaʻa ana i ka alpha-blocker therapy he 5 mg.

ʻO nā maʻi me chui pū ʻana use o CYP3A4 inā mea pale

No nā poʻe maʻi e lawe ana i nā mea hoʻopaneʻe CYP3A4 ikaika (e like me ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, a me atazanavir), ʻaʻole pono e hoʻonui ʻia kahi maʻi mua o 5 mg vardenafil.

Notes

He mea nui e hoʻomaopopo i ka hoʻoulu ʻana i ka moekolohe no ka pane ʻana i ka lāʻau lapaʻau. ʻAʻole hoʻonui ʻo Vardenafil i ka makemake i ka wahine a ʻaʻole e hana i kahi kūkulu me ka ʻole o ka hoʻoulu ʻana. Kūʻai vardenafil HCL pauka mai ka mea hoʻolako hilinaʻi hiki ke hōʻoia e loaʻa ana iāʻoe kahi huahana kiʻekiʻe e kōkua i ka hoʻokōʻana i ka maikaʻi maikaʻi loa no ka hoʻohanaʻana i ka manaʻo. Inā he pono kāu, ʻo AASraw kahi koho maikaʻi loa no ke kūʻai ʻana i ka pauka vardenafil hcl.

Ma hea e kūʻai ai i ka Vardenafil hydrochloride Powder?

Hiki ke kūʻaiʻia ka pauka Vardenafil hydrochloride mai nā mea kūʻai pūnaewele likeʻole e kūʻai aku i nā mea lāʻau. Ke hoʻoholo nei e kūʻai mai kahi mea hoʻolako pūnaewele, he mea nui e hōʻoia he kumu kaulana lākou, no ka mea nui o ka maikaʻi a me ka maʻemaʻe o ka huahana no nā noi olakino. E hōʻoia i ka mea kūʻai aku e hāʻawi nā kikoʻī huahana a me ka maikaʻi nā palapala hōʻoia, e like me ka palapala hōʻoia o ka loiloi.

Inā ʻoe e ʻimi nei i kahi kumu hilinaʻi no ke kūʻai ʻana i ka pauka vardenafil, KANAKA he koho kūpono paha. ʻO AASraw kahi hui e hāʻawi ana i kahi ākea o ka lāʻau lapaʻau mea waiwai, me ka pauka vardenafil. Hoʻohana pinepine ʻia kā lākou huahana e nā laboratories a me nā keʻena noiʻi no ka hoʻomohala ʻana a me ka hana ʻana i nā huahana olakino.

maka ʻO Vardenafil HCL Hōʻike hoʻāʻo pauda-HNMR

ʻO Vardenafil Hydrochloride Powder HNMR

He aha ka HNMR a he aha ka HNMR spectrum e haʻi iā ʻoe? ʻO H Nuclear Magnetic Resonance (INMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā hui pū ʻia i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR (a i ʻole e hoʻohālikelike ʻia i nā hale waihona puke spectral a i ʻole e hoʻokaʻawale pololei i ke ʻano kumu. e like me ka hoʻololi conformational, hoʻololi i ka pae, solubility, a me ka diffusion.

Vardenafil Hydrochloride pauka (224785-91-5) -COA

Vardenafil Hydrochloride pauka (224785-91-5) -COA

Pehea e kūʻai ai i ka Vardenafil HCL Powder mai AASraw?

❶I Hoʻokaʻaʻike iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu WhatsApp iā mākou, e hoʻopili aku kā mākou mea kūʻai aku (CSR) iā ʻoe i nā hola 12.

❷E hāʻawi iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.

❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala lawe, a me ka lā i manaʻo ʻia e hiki mai ai (ETA).

❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.

❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.

Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine

Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Hazem M. Abu Shawish
Keʻena Kemika, Koleke ʻEpekema, Ke Kulanui ʻo Al-Aqsa, Gaza, Palesetina
2. E. BISCHOFF
Mai ka Institute of Cardiovascular Research II, a me nā keʻena o ka noiʻi kemika, a me ka hoʻomohala ʻana i nā huahana a me nā Pharmacokinetics Preclinical, BAYER AG Pharmaceutical Business Group, Wuppertal, Kelemānia
3. MM Mabrouk
Keʻena o ka lāʻau lapaʻau analytical kemika, kumu o ka lāʻau lapaʻau, Tanta kulanui, Tanta, ʻAigupita
4. Engin Yurtcu
Obstetrics and Gynecology Department of Zekai Tahir Burak Women's Health and Research Hospital, Ankara, Turkey
5. Silvia Limoncella
Unit o Endocrinology, Keʻena o Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italia
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi ʻana a me ka hoʻomaikaʻi ʻana i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.

Reference

[1] Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, Spera G (Iulai 2009). "Nā hopena o ka hoʻokele vardenafil ma ka intravaginal ejaculatory latency time i nā kāne me ka ejaculation premature lōʻihi"Ka Palapala'Ōiwi Aupuni o kaʻIke. 21 (4):221–7. 

[2] Nā Kula Lapaʻau (Glen L.Stimmel,D., a me Mary A.Gutierrez,Pharm.D.) a me nā lāʻau lapaʻau (Glen L.Stimmel,Pharm.D.), Kulanui o Kaleponi Hema, Los Angeles, Kaleponi. "Ke aʻoʻana i nā maʻi e pili ana i nā pilikia pili i ka wahine: Priapism i hoʻokomoʻia i ka lāʻau".Medscape.Retrieved 2010-12-06.

[3] "Hoʻomaʻamaʻa erectile dysfunction hou ʻo Staxyn i ʻae ʻia ma US.- Hoʻoponopono lāʻau lapaʻau"mail.2010-06-21. Waiho ʻia mai ka mea kumu ma 2012-04-06.

[4] Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M (ʻOkakopa 2018). "ʻO nā mea lāʻau lapaʻau ʻaʻole i ʻae ʻia i loko o nā meaʻai meaʻai i hui pū ʻia me nā ʻōlelo aʻo a ka US Food and Drug Administration"Ka Honua JAMA Open. 1(6): 

[5] Lepor H, Lepor NE, Hill LA, Trohman RG (2008). "ʻO ka QT Interval a me ke koho ʻana o nā Alpha-Blockers no Benign Prostatic Hyperplasia". Nānā ma Urology. 10 (2):85–91.


E kiʻi i kahi hōʻaiʻē nui